Research programme: peptide therapeutics - Soricimed

Drug Profile

Research programme: peptide therapeutics - Soricimed

Alternative Names: SOR-C27; SOR-N54; Soricidin-derived C-series peptide therapeutics; Soricidin-derived N-series peptide therapeutics

Latest Information Update: 29 Oct 2013

Price : $50

At a glance

  • Originator Soricimed Biopharma
  • Class Drug conjugates; Non-opioid analgesics; Peptides
  • Mechanism of Action Apoptosis stimulants; Sodium channel antagonists; TRPV6 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Ovarian cancer; Pain; Prostate cancer

Most Recent Events

  • 15 Oct 2013 Pharmacodynamics data from a preclinical trial in Breast and Ovarian cancer released by Soricimed
  • 16 Aug 2012 Preclinical development is ongoing in Canada
  • 25 Oct 2011 Soricimed Biopharma licenses peptide technology from University Health Network
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top